Editor’s note: James Veltrop’s clients do not include Ranbaxy Labs.
When Teva Pharmaceuticals Industries Ltd. secured the rights to market a generic version of the blockbuster drug Neurontin in 2004, it looked like the company was in for a period of robust good health. After all, the brand-name version of the drug, used both to treat epilepsy and as a pain reliever, had generated more than $2 billion in sales for Pfizer Inc. in 2003. The generic version (gabapentin) was supposed to bring in hundreds of millions for Teva.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
